Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation

Journal of Neuroimmunology

Volumn 258, Issue 1-2, 2013, Pages 27-31

  Huang, Hui ^a   Ito, Kouichi ^a   Dangond, Fernando ^b   Dhib Jalbut, Suhayl ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b EMD SERONO INC   (United States)

Author keywords

B cell; B7.2; Costimulation; Interferon beta; Multiple sclerosis; Peripheral blood mononuclear cell

Indexed keywords

B7 ANTIGEN; B7.1 ANTIGEN; BETA1A INTERFERON; CD19 ANTIGEN; CD3 ANTIBODY; CD86 ANTIGEN; INTERLEUKIN 10; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TH2 CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84876738576     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.02.010     Document Type: Article

References (25)

1. Antel J., Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 2006, 180:3-8.
2. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., Davis S.J. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
3. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180:63-70.
4. Dangond F., Windhagen A., Groves C.J., Hafler D.A. Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity. J. Neuroimmunol. 1997, 76:132-138.
5. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
6. Duddy M., Bar-Or B. B-cells in multiple sclerosis. Int. MS J. 2006, 13:84-90.
7. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 2007, 178:6092-6099.
8. + B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J. Clin. Invest. 1997, 99:2664-2671.
9. Graber J.J., McGraw C.A., Kimbrough D., Dhib-Jalbut S. Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin. Neurol. Neurosurg. 2010, 112:583-591.
10. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
11. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39:285-294.
12. Kappos L., Li D., Calabresi P.A., O'Connor P.A., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., Hauser S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
13. Khan O., Dhib-Jalbut S.S. Interferon beta-1a (Avonex) serum levels following intramuscular injection in patients with relapsing-remitting multiple sclerosis. Neurology 1998, 51:738-742.
14. Khan O.A., Xia Q., Bever C.T., Johnson K.P., Panitch H.S., Dhib-Jalbut S.S. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996, 46:1639-1643.
15. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
16. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
17. Racke M.K., Ratts R.B., Arredondo L., Perrin P.J., Lovett-Racke A. The role of costimulation in autoimmune demyelination. J. Neuroimmunol. 2000, 107:205-215.
18. Ramgolam V.S., Sha Y., Marcus K.L., Choudhary N., Troiani L., Chopra M., Markovic-Plese S. B cells as a therapeutic target for IFN β in relapsing-remitting multiple sclerosis. J. Immunol. 2011, 186:4518-4526.
19. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001, 19:225-252.
20. Schreiner B., Mitsdoerffer M., Kieseier B.C., Chen L., Hartung H.P., Weller M., Wiendl H. Interferon-beta enhances monocyte and dendritic cell expression of B7.1 (PD-L1), a strong inhibitor of autologous T cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 2004, 155:172-182.
21. Šega S., Wraber B., Mesec A., Horvat A., Ihan A. IFN-β1a and IFN-β1b have different patterns of influence on cytokines. Clin. Neurol. Neurosurg. 2004, 106:255-258.
22. van der Merwe P.A., Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 2003, 21:659-684.
23. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., Hafler D.A. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 1995, 182:1985-1996.
24. Wu G.F., Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol. Clin. 2011, 29:257-278.
25. Zhang L., Yuan S., Cheng G., Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and TH-17-associated autoimmune inflammation. PLoS One 2011, 6:e28432.